Intravitreal steroids for the treatment of retinal diseases

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Sarao, Valentina ^a   Veritti, Daniele ^a   Boscia, Francesco ^b   Lanzetta, Paolo ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE; CORTICOSTEROID;

ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACTOGENESIS; CENTRAL RETINA VEIN OCCLUSION; CHEMOSIS; CHOROID DETACHMENT; CONJUNCTIVAL HEMORRHAGE; CORNEA EDEMA; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EYELID EDEMA; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOENDOPHTHALMITIS; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; SUBCAPSULAR CATARACT; SYMPATHETIC OPHTHALMIA; TEMPORAL ARTERITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; VITREOUS OPACITY; ANIMAL; INTRAVITREAL DRUG ADMINISTRATION; RETINA DISEASE; REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANIMALS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RETINAL DISEASES; TREATMENT OUTCOME;

EID: 84893198839     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/989501     Document Type: Article

References (115)

1. Nachod G. R., ACTH and cortisone in ocular disease. Journal of the American Medical Women's Association 1951 6 12 453 455 2-s2.0-40849102644
2. Kang B.-S., Chung E.-Y., Yun Y.-P., Lee M. K., Lee Y. R., Lee K.-S., Min K. R., Kim Y., Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biological and Pharmaceutical Bulletin 2001 24 6 701 703 2-s2.0-0034962040 10.1248/bpb.24.701 (Pubitemid 32586664)
3. Umland S. P., Nahrebne D. K., Razac S., Beavis A., Pennline K. J., Egan R. W., Billah M. M., The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon- γ production by cultured primary CD4+ T cells. Journal of Allergy and Clinical Immunology 1997 100 4 511 519 2-s2.0-0030777750
4. Floman N., Zor U., Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Investigative Ophthalmology & Visual Science 1977 16 1 69 73 2-s2.0-0017346446 (Pubitemid 8040411)
5. Bandi N., Kompella U. B., Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. European Journal of Pharmacology 2001 425 2 109 116 2-s2.0-0035839254 10.1016/S0014-2999(01)01192-X (Pubitemid 32739155)
6. Fischer S., Renz D., Schaper W., Karliczek G. F., In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. European Journal of Pharmacology 2001 411 3 231 243 2-s2.0-0035847131 10.1016/S0014-2999(00)00915-8 (Pubitemid 32119593)
7. Wilson C. A., Berkowitz B. A., Sato Y., Ando N., Handa J. T., De Juan E. Jr., Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Archives of Ophthalmology 1992 110 8 1155 1159 2-s2.0-0026655453
8. Naveh N., Weissman C., Prolonged corticosteroid treatment exerts transient inhibitory effect on prostaglandin E2 release from rabbits' eyes. Prostaglandins Leukotrienes and Essential Fatty Acids 1991 42 2 101 105 2-s2.0-0025967551 10.1016/0952-3278(91)90075-G
9. Lewis G. D., Campbell W. B., Johnson A. R., Inhibition of prostaglandin synthesis of glucocorticoids in human endothelial cells. Endocrinology 1986 119 1 62 69 2-s2.0-0022572140 (Pubitemid 16100708)
10. Heffernan J. T., Futterman S., Kalina R. E., Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Investigative Ophthalmology and Visual Science 1978 17 6 565 568 2-s2.0-0017825962 (Pubitemid 8357285)
11. Bhattacherjee P., Williams R. N., Eakins K. E., A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. Investigative Ophthalmology and Visual Science 1983 24 8 1143 1146 2-s2.0-0020550848 (Pubitemid 13048321)
12. Eisenstadt W. S., Cohen E. B., Osteoporosis and compression fractures from prolonged cortisone and corticotropin therapy. Annals of Allergy 1965 13 3 252 256
13. Livanou T., Ferriman D., James V. H., Recovery of hypothalamo-pituitary- adrenal function after corticosteroid therapy. The Lancet 1967 2 7521 856 859 2-s2.0-0014213480
14. Beer P. M., Bakri S. J., Singh R. J., Liu W., Peters G. B. III, Miller M., Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003 110 4 681 686 2-s2.0-0037398304 10.1016/S0161-6420(02)01969-3 (Pubitemid 36520063)
15. Geroski D. H., Edelhauser H. F., Transscleral drug delivery for posterior segment disease. Advanced Drug Delivery Reviews 2001 52 1 37 48 2-s2.0-0035980321 10.1016/S0169-409X(01)00193-4 (Pubitemid 32973637)
16. Bonini-Filho M. A., Jorge R., Barbosa J. C., Calucci D., Cardillo J. A., Costa R. A., Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Investigative Ophthalmology and Visual Science 2005 46 10 3845 3849 2-s2.0-32944465175 10.1167/iovs.05-0297 (Pubitemid 44264695)
17. Cardillo J. A., Melo L. A. S. Jr., Costa R. A., Skaf M., Belfort R. Jr., Souza-Filho A. A., Farah M. E., Kuppermann B. D., Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005 112 9 1557 1563 2-s2.0-24944566042 10.1016/j.ophtha.2005.03.023 (Pubitemid 41725412)
18. Özdek Ş., Bahçeci U. A., Gürelik G., Hasanreisolu B., Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. Journal of Diabetes and Its Complications 2006 20 4 246 251 2-s2.0-33745221158 10.1016/j.jdiacomp.2005.06.015
19. Choi Y. J., Oh I. K., Oh J. R., Huh K., Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean journal of ophthalmology 2006 20 4 205 209 2-s2.0-33847710254
20. Bakri S. J., Kaiser P. K., Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. American Journal of Ophthalmology 2005 139 2 290 294 2-s2.0-14244267199 10.1016/j.ajo.2004.09.038 (Pubitemid 40288274)
21. Cellini M., Pazzaglia A., Zamparini E., Leonetti P., Campos E. C., Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmology 2008 8, article 5 2-s2.0-41549088806 10.1186/1471-2415-8-5 (Pubitemid 351473488)
22. Veritti D., Lanzetta P., Perissin L., Bandello F., Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Investigative Ophthalmology and Visual Science 2009 50 5 2391 2397 2-s2.0-65549123001 10.1167/iovs.08-2518
23. Lanzetta P., Veritti D., Dal Mas G., Sarao V., Juxtascleral injection of a formulation of commercially available triamcinolone acetonide and viscoelastic agent in refractory diabetic macular edema. Paper Presented at: Retina Society 2011 Rome, Italy
24. Veritti D., Lanzetta P., Perissin L., Bandello F., Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Investigative Ophthalmology and Visual Science 2009 50 5 2391 2397 2-s2.0-65549123001 10.1167/iovs.08-2518
25. Machemer R., Sugita G., Tano Y., Treatment of intraocular proliferations with intravitreal steroids. Transactions of the American Ophthalmological Society 1979 77 171 180 2-s2.0-0018653468 (Pubitemid 10072805)
26. Avitabile T., Longo A., Reibaldi A., Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology 2005 140 4 695 702 2-s2.0-26844431631 10.1016/j.ajo.2005.05.021 (Pubitemid 41455312)
27. Gillies M. C., Sutter F. K. P., Simpson J. M., Larsson J., Ali H., Zhu M., Intravitreal triamcinolone for refractory diabetic macular edema. Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006 113 9 1533 1538 2-s2.0-33747623255 10.1016/j.ophtha.2006.02. 065 (Pubitemid 44292310)
28. Jonas J. B., Kamppeter B. A., Harder B., Vossmerbaeumer U., Sauder G., Spandau U. H. M., Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. Journal of Ocular Pharmacology and Therapeutics 2006 22 3 200 207 2-s2.0-33745884399 10.1089/jop.2006.22.200 (Pubitemid 44051133)
29. Hardman J. G., Limbird L. E., Gilman A. G., Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001 10th McGraw-Hill
30. Abelson M. B., Neufeld A. H., Topping T. M., Principles and Practice of Ophthalmology 1994 WB Saunders
31. Scholes G. N., O'Brien W. J., Abrams G. W., Kubicek M. F., Clearance of triamcinolone from vitreous. Archives of Ophthalmology 1985 103 10 1567 1569 2-s2.0-0022005708 (Pubitemid 15240750)
32. Audren F., Tod M., Massin P., Benosman R., Haouchine B., Erginay A., Caulin C., Gaudric A., Bergmann J.-F., Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Investigative Ophthalmology and Visual Science 2004 45 10 3435 3441 2-s2.0-4644318227 10.1167/iovs.03-1110 (Pubitemid 39298559)
33. Inoue M., Takeda K., Morita K., Yamada M., Tanigawara Y., Oguchi Y., Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. American Journal of Ophthalmology 2004 138 6 1046 1048 2-s2.0-11144253482 10.1016/j.ajo.2004.05.028 (Pubitemid 40040025)
34. Veritti D., Perissin L., Zorzet S., Lanzetta P., The effect of triamcinolone acetonide, sodium hyaluronate, and chondroitin sulfate on human endothelial cells: An in vitro study. European Journal of Ophthalmology 2011 21 6 75 79 2-s2.0-79960995603 10.5301/EJO.2010.6060
35. Audren F., Erginay A., Haouchine B., Benosman R., Conrath J., Bergmann J.-F., Gaudric A., Massin P., Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmologica Scandinavica 2006 84 5 624 630 2-s2.0-33748260374 10.1111/j.1600-0420.2006.00700.x (Pubitemid 44317541)
36. Hauser D., Bukelman A., Pokroy R., Katz H., Len A., Thein R., Parness-Yossifon R., Pollack A., Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008 28 6 825 830 2-s2.0-47749116519 10.1097/IAE.0b013e318165767e
37. Lam D. S. C., Chan C. K. M., Mohamed S., Lai T. Y. Y., Li K. K. W., Li P. S. H., Tsang C.-W., Chan W.-M., Shanmugam M. P., A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. British Journal of Ophthalmology 2007 91 2 199 203 2-s2.0-33846845026 10.1136/bjo.2006.102848 (Pubitemid 46202869)
38. Massin P., Audren F., Haouchine B., Erginay A., Bergmann J.-F., Benosman R., Caulin C., Gaudric A., Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004 111 2 218 224 2-s2.0-0842267262 10.1016/j.ophtha.2003.05.037 (Pubitemid 38183217)
39. Bandello F., Pognuz D. R., Pirracchio A., Polito A., Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2004 242 12 1024 1027 2-s2.0-10844231900 10.1007/s00417-004-0911-1 (Pubitemid 40003957)
40. Yilmaz T., Weaver C. D., Gallagher M. J., Cordero-Coma M., Cervantes-Castaneda R. A., Klisovic D., Lavaque A. J., Larson R. J., Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009 116 5 902 913 2-s2.0-65349122995 10.1016/j.ophtha.2009.02.002
41. Diabetic Retinopathy Clinical Research Network, Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology 2009 127 3 245 251 2-s2.0-62449171859 10.1001/archophthalmol.2008.610
42. Augustin A. J., Schmidt-Erfurth U., Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology 2006 141 4 638 645 2-s2.0-33645309102 10.1016/j.ajo.2005.11.058
43. Spaide R. F., Sorenson J., Maranan L., Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003 110 8 1517 1525 2-s2.0-0042029477 10.1016/S0161-6420(03)00544-X (Pubitemid 36962483)
44. Singh C. N., Saperstein D. A., Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008 28 6 789 793 2-s2.0-47749114980 10.1097/IAE.0b013e31817082d7
45. Rechtman E., Allen V. D., Danis R. P., Pratt L. M., Harris A., Speicher M. A., Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. American Journal of Ophthalmology 2003 136 4 739 741 2-s2.0-0141793688 10.1016/S0002-9394(03)00389-1 (Pubitemid 37153194)
46. Ip M. S., Scott I. U., van Veldhuisen P. C., Oden N. L., Blodi B. A., Fisher M., Singerman L. J., Tolentino M., Chan C. K., Gonzalez V. H., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology 2009 127 9 1101 1114 2-s2.0-70349243148 10.1001/archophthalmol.2009.234
47. Scott I. U., Ip M. S., van Veldhuisen P. C., Oden N. L., Blodi B. A., Fisher M., Chan C. K., Gonzalez V. H., Singerman L. J., Tolentino M., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Archives of Ophthalmology 2009 127 9 1115 1128 2-s2.0-70349247768 10.1001/archophthalmol.2009.233
48. Jonas J. B., Kreissig I., Degenring R. F., Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmologica Scandinavica 2003 81 5 540 541 2-s2.0-0142061608 10.1034/j.1600-0420.2003.00130.x (Pubitemid 37265680)
49. Chen W., Chen H., Hou P., Fok A., Hu Y., Lam D. S. C., Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina 2011 31 6 1137 1142 2-s2.0-79958295846 10.1097/IAE.0b013e3181fe5427
50. Jonas J. B., Kreissig I., Degenring R. F., Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. American Journal of Ophthalmology 2003 136 2 384 386 2-s2.0-0042349342 10.1016/S0002-9394(03)00230-7 (Pubitemid 36904101)
51. Alldredge C. D., Garretson B. R., Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003 23 1 113 116 2-s2.0-0037298797 10.1097/00006982-200302000-00022 (Pubitemid 36348497)
52. Jonas J. B., Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. American Journal of Ophthalmology 2004 137 2 367 368 2-s2.0-1242271206 10.1016/S0002-9394(03)00899-7 (Pubitemid 38221022)
53. Jonas J. B., Kreissig I., Degenring R. F., Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. European Journal of Ophthalmology 2003 13 6 575 576 2-s2.0-0642281860 (Pubitemid 38208842)
54. Jonas J. B., Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment. British Journal of Ophthalmology 2004 88 4 587 588 2-s2.0-1542351664 10.1136/bjo.2003.028688 (Pubitemid 38437891)
55. Sutter F. K. P., Gillies M. C., Intravitreal triamcinolone for radiation-induced macular edema. Archives of Ophthalmology 2003 121 10 1491 1493 2-s2.0-0141885196 10.1001/archopht.121.10.1491 (Pubitemid 37243759)
56. Ozdemir H., Karacorlu M., Karacorlu S., Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmologica Scandinavica 2005 83 2 248 251 2-s2.0-17644394246 10.1111/j.1600-0420.2005.00395.x (Pubitemid 40561839)
57. Karacorlu M., Arf Karacorlu S., Ozdemir H., Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. European Journal of Ophthalmology 2006 16 3 481 483 2-s2.0-33745876841 (Pubitemid 44049297)
58. Couch S. M., Bakri S. J., Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clinical Ophthalmology 2009 3 1 41 47 2-s2.0-77952203082
59. Lee C. M., Olk R. J., Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991 98 10 1594 1602 2-s2.0-0026324005
60. Diabetic Retinopathy Clinical Research Network, A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008 115 9 1447 1449 10.1016/j.ophtha.2008.06.015
61. Diabetic Retinopathy Clinical Research Network, Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011 118 4 609 614 2-s2.0-79953299899 10.1016/j.ophtha.2010.12.033
62. Choi K. S., Chung J. K., Lim S. H., Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Korean Journal of Ophthalmology 2007 21 1 11 17 2-s2.0-34250182396 10.3341/kjo.2007.21.1.11
63. Kaderli B., Avci R., Gelisken O., Yucel A. Â., Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. International Ophthalmology 2005 26 6 207 214 2-s2.0-33947264095 10.1007/s10792-007-9042-0 (Pubitemid 46415832)
64. Zacks D. N., Johnson M. W., Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 2005 25 2 135 140 2-s2.0-14944378020 10.1097/00006982-200502000-00003 (Pubitemid 40365935)
65. Zein W. M., Noureddin B. N., Jurdi F. A., Schakal A., Bashshur Z. F., Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina 2006 26 2 137 142 2-s2.0-33645751925 10.1097/00006982-200602000-00002 (Pubitemid 44400706)
66. Bandello F., Polito A., Pognuz D. R., Monaco P., Dimastrogiovanni A., Paissios J., Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Archives of Ophthalmology 2006 124 5 643 650 2-s2.0-33646486870
67. Maia O. O. Jr., Takahashi B. S., Costa R. A., Scott I. U., Takahashi W. Y., Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. American Journal of Ophthalmology 2009 147 2 291 597 2-s2.0-58249105907 10.1016/j.ajo.2008.08.024
68. Kim J. E., Pollack J. S., Miller D. G., Mittra R. A., Spaide R. F., ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008 28 5 735 740 2-s2.0-43249106823 10.1097/IAE.0b013e318163194c (Pubitemid 351655127)
69. Jonas J. B., Kamppeter B. A., Harder B., Vossmerbaeumer U., Sauder G., Spandau U. H. M., Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. Journal of Ocular Pharmacology and Therapeutics 2006 22 3 200 207 2-s2.0-33745884399 10.1089/jop.2006.22.200 (Pubitemid 44051133)
70. Gillies M. C., Simpson J. M., Gaston C., Hunt G., Ali H., Zhu M., Sutter F., Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009 116 11 2182 2187 2-s2.0-70350574742 10.1016/j.ophtha.2009.04.049
71. Eliott D., Dugel P. U., Cantrill H. L., I-vation TA: 18 month results from phase I safety and preliminary efficacy study. Presented at Annual Meeting of the Association for Research in Vision and Ophthalmology 2008 Fort Lauderdale, Fla, USA
72. Jonas J. B., Akkoyun I., Kamppeter B., Kreissig I., Degenring R. F., Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005 19 1 65 71 2-s2.0-13244277526 10.1038/sj.eye.6701395 (Pubitemid 40192642)
73. Jonas J., Paques M., Monés J., Glacet-Bernard A., Retinal vein occlusions. Developments in Ophthalmology 2010 47 111 135 2-s2.0-77956377644 10.1159/000320076
74. Lim J. I., Fung A. E., Wieland M., Hung D., Wong V., Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion. Ophthalmology 2011 118 7 1416 1422 2-s2.0-79959998734 10.1016/j.ophtha.2010.12.029
75. Enaida H., Hata Y., Ueno A., Nakamura T., Hisatomi T., Miyazaki M., Fujisawa K., Sakamoto T., Ishibashi T., Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina 2003 23 6 764 770 2-s2.0-0347361621 10.1097/00006982-200312000-00003 (Pubitemid 38040574)
76. Jonas J. B., Kamppeter B., Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea 2006 25 2 240 241 2-s2.0-33644833529 10.1097/01.ico.0000176614.73332.58 (Pubitemid 43362732)
77. Jonas J. B., Vossmerbaeumer U., Kamppeter B. A., Chronic prephthisical ocular hypotony treated by intravitreal triamcinolone acetonide. Acta Ophthalmologica Scandinavica 2004 82 5 637 2-s2.0-6344219798 10.1111/j.1600-0420.2004.00319.x (Pubitemid 39386991)
78. Tamura H., Miyamoto K., Kiryu J., Miyahara S., Katsuta H., Hirose F., Musashi K., Yoshimura N., Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Investigative Ophthalmology and Visual Science 2005 46 4 1440 1444 2-s2.0-18244391221 10.1167/iovs.04-0905 (Pubitemid 41685887)
79. Williams G. A., Haller J. A., Kuppermann B. D., Blumenkranz M. S., Weinberg D. V., Chou C., Whitcup S. M., Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or irvine-gass syndrome. American Journal of Ophthalmology 2009 147 6 1048 1054 2-s2.0-67349125916 10.1016/j.ajo.2008.12.033
80. Hyung Woo Kwak H. W. K., D'Amico D. J., Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Archives of Ophthalmology 1992 110 2 259 266 2-s2.0-0026515817
81. Haller J. A., Kuppermann B. D., Blumenkranz M. S., Williams G. A., Weinberg D. V., Chou C., Whitcup S. M., Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology 2010 128 3 289 296 2-s2.0-77749330682 10.1001/archophthalmol.2010.21
82. Chang-Lin J.-E., Attar M., Acheampong A. A., Robinson M. R., Whitcup S. M., Kuppermann B. D., Welty D., Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investigative Ophthalmology and Visual Science 2011 52 1 80 86 2-s2.0-79251481714 10.1167/iovs.10-5285
83. Haller J. A., Bandello F., Belfort R. Jr., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y.-H., Jacques M.-L., Jiao J., Li X.-Y., Whitcup S. M., Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010 117 6 1134 1146 2-s2.0-77952882990 10.1016/j.ophtha.2010.03.032
84. Kuppermann B. D., Blumenkranz M. S., Haller J. A., Williams G. A., Weinberg D. V., Chou C., Whitcup S. M., Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology 2007 125 3 309 317 2-s2.0-33947275043 10.1001/archopht.125.3.309 (Pubitemid 46425557)
85. Boyer D. S., Faber D., Gupta S., Patel S. S., Tabandeh H., Li X.-Y., Liu C. C., Lou J., Whitcup S. M., Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011 31 5 915 923 2-s2.0-79955558683 10.1097/IAE.0b013e318206d18c
86. Augustin A. J., Puls S., Offermann I., Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007 27 2 133 140 2-s2.0-33846973642 10.1097/IAE.0b013e3180323de7
87. Bakri S. J., Couch S. M., McCannel C. A., Edwards A. O., Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009 29 5 573 578 2-s2.0-66349105686 10.1097/IAE.0b013e3181a46a8a
88. Ehmann D., García R., Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Canadian Journal of Ophthalmology 2010 45 1 36 40 2-s2.0-76149131060 10.3129/i09-243
89. Kupperman B., Safety and efficacy of dexamethasone intravitreal implant as adjunctive therapy to Lucentis in patients with choroidal neovascularization secondary to age-related macular degeneration. Proceedings of the 33rd Annual Macular Society Meeting February 2010 Tucson, Ariz, USA
90. Loewenstein A., Kuppermann B. D., Weinberger D., Safety and efficacy of Ozurdex (dexamethasone intravitreal implant) as adjunctive therapy to Lucentis in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Paper Presented at: Association for Research in Vision and Ophthalmology Fort Lauderdale, Fla, USA May 2010
91. Singer M., Patel S. S., Uy H. S., Li X.-Y., Liu C., Whitcup S. M., Dexamethasone intravitreal implant alone and as an adjunct to ranibizumab for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Paper Presented at: Retina Society Annual Meeting 2011 Rome, Italy
92. QLT, QLT Announces final results from its RADICAL study evaluating Verteporfin PDT. (Visudyne) combination therapy in exudative AMD, 2012
93. Lowder C., Belfort R. Jr., Lightman S., Foster C. S., Robinson M. R., Schiffman R. M., Li X.-Y., Cui H., Whitcup S. M., Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology 2011 129 5 545 553 2-s2.0-79952947252 10.1001/archophthalmol.2010. 339
94. Driot J.-Y., Novack G. D., Rittenhouse K. D., Milazzo C., Pearson P. A., Ocular pharmacokinetics of fluocinolone acetonide after Retisert ™ intravitreal implantation in rabbits over a 1-year period. Journal of Ocular Pharmacology and Therapeutics 2004 20 3 269 275 2-s2.0-3042763334 10.1089/1080768041223611 (Pubitemid 38849806)
95. Jaffe G. J., Yang C. H., Guo H., Denny J. P., Lima C., Ashton P., Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Investigative Ophthalmology and Visual Science 2000 41 11 3569 3575 2-s2.0-0033771171
96. Jaffe G. J., Martin D., Callanan D., Pearson P. A., Levy B., Comstock T., Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 113 6 1020 1027 2-s2.0-33646925637 10.1016/j.ophtha.2006.02. 021 (Pubitemid 43795240)
97. Campochiaro P. A., Brown D. M., Pearson A., Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012 119 10 2125 2132 10.1016/j.ophtha.2012.04.030
98. Scott I. U., Flynn H. W. Jr., Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007 27 1 10 12 2-s2.0-33846244134 10.1097/IAE.0b013e3180307271 (Pubitemid 46095824)
99. Jonas J. B., Kreissig I., Degenring R. F., Endophthalmitis after intravitreal injection of triamcinolone acetonide. Archives of Ophthalmology 2003 121 11 1663 1664 2-s2.0-0242443375 10.1001/archopht.121.11.1663-a
100. Jonas J. B., Kreissig I., Spandau U. H., Harder B., Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. American Journal of Ophthalmology 2006 141 3 579 580 2-s2.0-33144475205 10.1016/j.ajo.2005.10.007 (Pubitemid 43265975)
101. Carrero J. L., Barcia M. G., Flores I. P., Sterile endophthalmitis after benzyl alcohol-filtered triamcinolone acetonide injection. Archives of Ophthalmology 2008 126 1 142 143 2-s2.0-38349073483 10.1001/archophthalmol.2007. 20
102. Sutter F. K. P., Gillies M. C., Pseudo-endophthalmitis after intravitreal injection of triamcinolone. British Journal of Ophthalmology 2003 87 8 972 974 2-s2.0-0041705920 10.1136/bjo.87.8.972 (Pubitemid 36936293)
103. Park H. Y., Yi K., Kim H. K., Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean Journal of Ophthalmology 2005 19 2 122 127 2-s2.0-24944540006
104. Bakri S. J., Beer P. M., The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surgery Lasers and Imaging 2003 34 5 386 390 2-s2.0-0042415003 (Pubitemid 37100154)
105. Detry-Morel M., Escarmelle A., Hermans I., Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bulletin de la Societe Belge d'Ophtalmologie 2004 292 45 51 2-s2.0-3843068861
106. Jonas J. B., Degenring R., Vossmerbauemer U., Kamppeter B., Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. European Journal of Ophthalmology 2005 15 4 462 464 2-s2.0-23844475814 (Pubitemid 41152966)
107. Gillies M. C., Islam F. M. A., Zhu M., Larsson J., Wong T. Y., Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. British Journal of Ophthalmology 2007 91 10 1323 1326 2-s2.0-34848902025 10.1136/bjo.2006.113167 (Pubitemid 47492866)
108. Çekiç O., Chang S., Tseng J. J., Akar Y., Barile G. R., Schiff W. M., Cataract progression after intravitreal triamcinolone injection. American Journal of Ophthalmology 2005 139 6 993 998 2-s2.0-20444483245 10.1016/j.ajo.2005.01.022 (Pubitemid 40813309)
109. Jonas J. B., Degenring R., Kreissig I., Akkoyun I., Safety of intravitreal high-dose reinjections of triamcinolone acetonide. American Journal of Ophthalmology 2004 138 6 1054 1055 2-s2.0-11144260931 10.1016/j.ajo.2004.06. 041 (Pubitemid 40040030)
110. Lang Y., Zemel E., Miller B., Perlman I., Retinal toxicity of intravitreal Kenalog in albino rabbits. Retina 2007 27 6 778 788 2-s2.0-34447330433 10.1097/IAE.0b013e318030c517 (Pubitemid 47051776)
111. Tokuda K., Tsukamoto T., Fujisawa S., Matsubara M., Evaluation of toxicity due to vital stains in isolated rat retinas. Acta Ophthalmologica Scandinavica 2004 82 2 189 194 2-s2.0-1942516493 10.1111/j.1600-0420.2004.00224. x (Pubitemid 38515376)
112. Kivilcim M., Peyman G. A., El-Dessouky E.-S., Kazi A. A., Cheema R., Hegazy H., Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surgery and Lasers 2000 31 6 474 478 2-s2.0-0033743504
113. Narayanan R., Mungcal J. K., Kenney M. C., Seigel G. M., Kuppermann B. D., Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Investigative Ophthalmology and Visual Science 2006 47 2 722 728 2-s2.0-33644864608 10.1167/iovs.05-0772 (Pubitemid 46768403)
114. Yeung C. K., Chan K. P., Chiang S. W. Y., Pang C. P., Lam D. S. C., The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Investigative Ophthalmology and Visual Science 2003 44 12 5293 5300 2-s2.0-0344851534 10.1167/iovs.03-0490 (Pubitemid 37475401)
115. Haller J. A., Dugel P., Weinberg D. V., Chou C., Whitcup S. M., Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009 29 1 46 51 2-s2.0-61549134800 10.1097/IAE.0b013e318188c814